Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BridgeBio
Pharma
JPM25: BridgeBio's cardiomyopathy drug is off to a roaring start
Less than two months after scoring an FDA nod, BridgeBio's cardiomyopathy drug Attruby is already muscling in on Vyndaqel's turf.
Fraiser Kansteiner
Jan 13, 2025 9:40pm
Key drugs from Merck, Bayer and Gilead win EMA backing
Dec 13, 2024 10:33am
Look out, Pfizer: BridgeBio gains 'best-case' FDA nod for Attruby
Nov 25, 2024 7:59am
For $100M, BridgeBio partners with Kyowa Kirin on infigratinib
Feb 7, 2024 12:53pm
Pfizer's tafamidis will hold its own against new meds: analysts
Sep 18, 2023 3:05pm
Rare disease player BridgeBio draws buyout interest: Bloomberg
Mar 28, 2023 11:10am
